JPH0449536B2 - - Google Patents
Info
- Publication number
- JPH0449536B2 JPH0449536B2 JP58209712A JP20971283A JPH0449536B2 JP H0449536 B2 JPH0449536 B2 JP H0449536B2 JP 58209712 A JP58209712 A JP 58209712A JP 20971283 A JP20971283 A JP 20971283A JP H0449536 B2 JPH0449536 B2 JP H0449536B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- general formula
- compound
- reaction
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 48
- -1 methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy Chemical group 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 150000002118 epoxides Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 150000001299 aldehydes Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000003884 phenylalkyl group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- FBYIJIHPWCXRHH-UHFFFAOYSA-N 1,4,5,8-tetramethoxynaphthalene-2-carbaldehyde Chemical compound O=CC1=CC(OC)=C2C(OC)=CC=C(OC)C2=C1OC FBYIJIHPWCXRHH-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
- UZGZPQGJNHDHKO-UHFFFAOYSA-N (1-methoxynaphthalen-2-yl)methanol Chemical compound C1=CC=C2C(OC)=C(CO)C=CC2=C1 UZGZPQGJNHDHKO-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000003890 2-phenylbutyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010058177 Hyperkinetic heart syndrome Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- CALQKRVFTWDYDG-UHFFFAOYSA-N butan-1-amine;hydroiodide Chemical compound [I-].CCCC[NH3+] CALQKRVFTWDYDG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UNFUYWDGSFDHCW-UHFFFAOYSA-N monochlorocyclohexane Chemical compound ClC1CCCCC1 UNFUYWDGSFDHCW-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QAXZWHGWYSJAEI-UHFFFAOYSA-N n,n-dimethylformamide;ethanol Chemical compound CCO.CN(C)C=O QAXZWHGWYSJAEI-UHFFFAOYSA-N 0.000 description 1
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000009157 neurocirculatory asthenia Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
ãçºæã®è©³çްãªèª¬æã
æ¬çºæã¯ïŒïŒïŒïŒïŒïŒïŒâããã©ã¢ã«ã³ãã·ã
ãã¿ã¬ã³èªå°äœåã³ãã®å¡©ã«é¢ããã
æ¬çºæã®äžèšèªå°äœã¯ãæç®æªèŒã®æ°èŠååç©
ã§ãã€ãŠãäžèšäžè¬åŒ(1)ã§è¡šããããã
ãåŒäžR1ã¯äœçŽã¢ã«ã³ãã·åºã瀺ããR2åã³
R3ã¯äžæ¹ãæ°Žé
žåºåã¯äœçŽã¢ã«ã«ãã€ã«ãªãã·
åºã瀺ãã仿¹ãåºãåŒãã瀺ãã該åºã«ã
ããŠR4åã³R5ã¯åäžåã¯çžç°ãªã€ãŠæ°ŽçŽ ååã
äœçŽã¢ã«ãã«åºãã·ã¯ãã¢ã«ãã«åºãããšãã«ç°
äžã«çœ®æåºãšããŠäœçŽã¢ã«ã³ãã·åºãæããããš
ã®ããããšãã«åºåã¯ããšãã«ç°äžã«çœ®æåºãšã
ãŠäœçŽã¢ã«ã³ãã·åºãæããããšã®ããããšãã«
äœçŽã¢ã«ãã«åºã瀺ãããŸãR4åã³R5ã¯é
žçŽ å
åãããã¯çªçŽ ååãä»ããããã¯ä»ããããšãª
ãäºã«çµåããŠã飿¥ããçªçŽ ååãšå
±ã«è€çŽ ç°
åºã圢æããŠãããã該è€çŽ ç°åºã¯æŽã«ããšãã«
äœçŽã¢ã«ãã«åºã眮æåºãšããŠæããŠããŠãã
ããã
äžèšäžè¬åŒ(1)äžãR1ã§å®çŸ©ãããäœçŽã¢ã«ã³
ãã·åºãšããŠã¯ãäŸãã°ã¡ããã·ããšããã·ãã
ãããã·ãã€ãœããããã·ããããã·ãã€ãœãã
ãã·ãsecâãããã·ãtertâãããã·åºçãäŸ
瀺ã§ããã
R2åã³R3ã§å®çŸ©ãããäœçŽã¢ã«ã«ãã€ã«ãªã
ã·åºãšããŠã¯ãäŸãã°ã¢ã»ããã·ãããããªãã«
ãªãã·ããããªã«ãªãã·ãã€ãœãããªã«ãªãã·ã
ãã¬ãªã«ãªãã·ãã€ãœãã¬ãªã«ãªãã·åºçãäŸç€º
ã§ããã
ãŸãåºãåŒãã圢æããR4åã³R5ã§ç€ºã
ããäœçŽã¢ã«ãã«åºãšããŠã¯ãäŸãã°ã¡ãã«ããš
ãã«ããããã«ãã€ãœãããã«ãããã«ãã€ãœã
ãã«ãsecâããã«ãtertâããã«åºçããã·ã¯
ãã¢ã«ãã«åºãšããŠã¯ãã·ã¯ããããã«ãã·ã¯ã
ããã«ãã·ã¯ããã³ãã«ãã·ã¯ãããã·ã«ãã·ã¯
ããããã«åã³ã·ã¯ããªã¯ãã«åºããããšãã«ç°
äžã«çœ®æåºãšããŠäœçŽã¢ã«ã³ãã·åºãæããããš
ã®ããããšãã«åºãšããŠã¯ãäŸãã°ããšãã«ãïŒ
âã¡ããã·ããšãã«ãïŒâã¡ããã·ããšãã«ãïŒ
âãããã·ããšãã«ãïŒâã¡ããã·âïŒâãšãã
ã·ããšãã«ãïŒïŒïŒâãžã¡ããã·ããšãã«ãïŒïŒ
ïŒâãžããããã·ããšãã«ãïŒïŒïŒïŒïŒâããªã¡
ããã·ããšãã«ãïŒïŒïŒïŒïŒâããªãšããã·ããš
ãã«åºçããæŽã«ããšãã«ç°äžã«çœ®æåºãšããŠäœ
çŽã¢ã«ã³ãã·åºãæããããšã®ããããšãã«äœçŽ
ã¢ã«ãã«åºãšããŠã¯ãäŸãã°ãã³ãžã«ãαâããš
ããã«ãβâããšããã«ãïŒâããšãã«ããã
ã«ãïŒâããšãã«ãããã«ãïŒâããšãã«ããã
ã«ãïŒâããšãã«ããã«ãïŒâããšãã«ããã«ã
ïŒâããšãã«ããã«ãïŒâããšãã«ããã«ãïŒâ
ããšãã«ãã³ãã«ãïŒâããšãã«ãã³ãã«ãïŒâ
ããšãã«ãã³ãã«ãïŒâããšãã«ããã·ã«ãïŒâ
ããšãã«ããã·ã«ãïŒâããšãã«ããã·ã«ãïŒïŒ
ïŒâãžã¡ãã«âïŒâããšãã«ãšãã«åºçã®é眮æ
ã®ããšãã«ã¢ã«ãã«åºåã³äŸãã°ïŒâã¡ããã·ã
ã³ãžã«ãïŒâãšããã·âβâããšããã«ãïŒâã
ãããã·âβâããšããã«ãïŒâïŒïŒïŒïŒâãžã¡
ããã·ããšãã«ïŒãããã«ãïŒâïŒïŒïŒïŒâãžãš
ããã·ããšãã«ïŒããã«ãïŒïŒïŒïŒïŒâããªã¡ã
ãã·ãã³ãžã«ãïŒïŒïŒâãžã¡ããã·âβâããšã
ãã«ãïŒâïŒïŒïŒïŒâãžã¡ããã·ããšãã«ïŒãã
ã·ã«åºçã®çœ®æããšãã«ã¢ã«ãã«åºã倫ã
äŸç€ºã
ãããšãã§ããã
æŽã«äžèšåºãåŒãã圢æãåŸãè€çŽ ç°åºãš
ããŠã¯ãäŸãã°ïŒâãããªãžãã«ããããªãžãã
ããã©ãžãã«ãã¢ã«ããªãåºçãäŸç€ºã§ããããš
ãã«äœçŽã¢ã«ãã«çœ®æã®äžèšè€çŽ ç°åºãšããŠã¯ã
äžèšé眮æã®ããšãã«ã¢ã«ãã«åºã§çœ®æãããã
ãã©ãžãã«åºäŸãã°ïŒ®âãã³ãžã«ããã©ãžãã«ã
âαâããšããã«ããã©ãžãã«ãâβâããš
ããã«ããã©ãžãã«åºçãäŸç€ºããããšãã§ã
ãã
äžèšäžè¬åŒ(1)ã§è¡šããããæ¬çºæèªå°äœåã³ã
ã®å¡©å³ã¡ç¡æ©ãããã¯ææ©é
žã®ä»å å¡©ã¯ãããã
ãå¿èçŸæ£åã³æ¬èœæ§é«è¡å§çã®é«è¡å§çã®æ²»ç
åã³äºé²å¹æãæããŠãããä¹çã®è¬çäœçšãå©
çšããå»è¬åãšããŠãäŸãã°ãã€è¡æ§å¿äžå
šãç
å¿çãå¿çæ¢å¡ãé«è¡å§ãå¿èäžæŽèãéå亢é²
æ§å¿èçå矀çã®æ²»çåã³äºé²è¬ãšããŠæçšã§ã
ãã
æ¬çºæèªå°äœã¯ãçš®ã
ã®æ¹æ³ã«ãã補é ãã
ãããã®å¥œãŸããå
·äœäŸãäžèšåå¿å·¥çšåŒã«ç€ºã
詳述ããã
ãåŒäžR1ãR4åã³R5ã¯åèšã«åããR2â²åã³
R3â²ã¯äžæ¹ãæ°Žé
žåºã§ä»æ¹ãåºãåŒãïŒR4å
ã³R5ã¯åèšã«åãïŒã瀺ãããŸãR2â³åã³R3â³ã¯
äžæ¹ãäœçŽã¢ã«ã«ãã€ã«ãªãã·åºã§ä»æ¹ãåº
ãåŒãïŒR4åã³R5ã¯åèšã«åãïŒã瀺ããã
åå¿è¡çšåŒâïŒã«ããã°ãäžè¬åŒ(2)ã§è¡šããã
ãå
¬ç¥ã®ã¢ã«ãããããšããã·äœã«å€æãããŠåŸ
ãããäžè¬åŒ(3)ã®ãšããã·ãã«ãäžè¬åŒ(4)ã®ã¢ã
ã³ãåå¿ãããããšã«ããäžè¬åŒ(1)äžR2åã³R3
ã®äžæ¹ãæ°Žé
žåºã§ããæ¬çºæååç©ïŒ1aïŒãå
åŸã§ãã該ååç©ïŒ1aïŒãã¢ã·ã«ååå¿ããã
ããšã«ããäžè¬åŒ(1)äžR2åã³R3ã®äžæ¹ãäœçŽã¢
ã«ã«ãã€ã«ãªãã·åºã§ããæ¬çºæååç©ïŒ1bïŒ
ãååŸã§ããã
äžèšã«ãããäžè¬åŒ(2)ã®ã¢ã«ãããã®ãšããã·
ååå¿ã¯ãå
¬ç¥ã®æ¹æ³ãäŸãã°ã¡ã«ã¯ã«ïŒG.
MašrklïŒãã®æ¹æ³ãAngew.Chem.ïŒ85ïŒ867
ïŒ1973ïŒãã«æºããŠå®æœããããšãã§ãããå³ã¡çŽ
ïŒãïŒã¢ã«ïŒ
ã®çžé¢ç§»åè§ŠåªãäŸãã°ãã³ãžã«ã
ãªãšãã«ã¢ã³ã¢ããŠã ã¯ãã©ã€ããããã©âïœâ
ããã«ã¢ã³ã¢ããŠã ãšãŒãã€ãçã®ïŒçŽã¢ã³ã¢ã
ãŠã å¡©ã®ååšäžã50ïŒ
æ°Žé
žåã¢ã«ã«ãªãšãžã¯ãã«
ã¡ã¿ã³ãšã®äºçžç³»ã§ãäžè¬åŒ(2)ã®ã¢ã«ããããšã
ããã«å¯ŸãçŽïŒã1.3åã¢ã«éã®ããªã¡ãã«ã¹ã«
ãããŠã ãšãŒãã€ããšãåå¿ãããããšã«ããè¡
ãªãããã該åå¿ã¯çŽ50âååŸã®æž©åºŠæ¡ä»¶äžã«ã
éåžž24ã48æéã§å®çµããããã«ããäžè¬åŒ(3)ã®
ãšããã·ããåŸãã該ãšããã·ã(3)ã¯æç®æªèŒã®
æ°èŠååç©ã§ãããæ¬çºæã®ïŒïŒïŒïŒïŒïŒïŒâã
ãã©ã¢ã«ã³ãã·ããã¿ã¬ã³èªå°äœã®åæäžéäœãš
ããŠéèŠãªãã®ã§ããã
äžèšãšããã·ã(3)ãšäžè¬åŒ(4)ã§è¡šããããå
¬ç¥
ã®ã¢ãã³ãšã®åå¿ã¯ãéåžžé©åœãªæº¶åªäžã§è¡ãªã
ãããæº¶åªãšããŠã¯åå¿ã«æªåœ±é¿ãäžããªãåçš®
ã®ãã®ã䜿çšã§ããç¹ã«ã¡ã¿ããŒã«ããšã¿ããŒ
ã«ãã€ãœãããããŒã«ãtertâãã¿ããŒã«ãã€ãœ
ã¢ãã«ã¢ã«ã³ãŒã«çã®ã¢ã«ã³ãŒã«ç³»æº¶åªã奜é©ã§
ããããšããã·ã(3)ã«å¯Ÿããã¢ãã³(4)ã®äœ¿çšå²å
ã¯ç¹ã«éå®ãããªãããéåžžå°ãªããšãåœéãäž
è¬ã«ã¯çŽïŒã20ååœéã®ç¯å²ãšããããåå¿ã¯çŽ
25âãæº¶åªã®æ²žç¹ç¯å²ã®æž©åºŠæ¡ä»¶äžã«ãéåžžçŽïŒ
æéã10æ¥éã§è¡ãªãããããã®åå¿ã«ããäžè¬
åŒïŒ1aïŒã§è¡šããããæ¬çºæååç©ãåŸããã
ãã¯éåžžäžè¬åŒïŒ1aïŒäžãR2â²ãæ°Žé
žåºã§ããå
åç©ãšãR3â²ãæ°Žé
žåºã§ããååç©ãšã®æ··åç©ã§
ãããäžè¬ã«ã¯åæãšããäžè¬åŒ(3)ã®ãšããã·ã
ãããã¿ã¬ã³ç°ã«é»åäŸäžåºã§ããã¢ã«ã³ãã·åº
ïŒR1ïŒãæããŠãããããR3â²ãæ°Žé
žåºã§ããå
åç©ãäž»æç©äœãšããŠåŸãããå Žåãå€ããä¹ç
ã®æ··åç©ã¯åžžæ³ã«åŸãåé¢ããããšãã§ããã
äžèšåå¿ã«åŒãç¶ãäžè¬åŒïŒ1aïŒã®ååç©ã®
ã¢ã·ã«ååå¿ã¯ãéåžžã®æ¹æ³ã«åŸããå¡©åºäŸãã°
ããªãžã³ãããªãšãã«ã¢ãã³çã®ååšäžã«ãã¢ã·
ã«åå€äŸãã°äœçŽã¢ã«ãã«ã«ã«ãã³é
žã®ç¡æ°Žç©ã
ããã¯é
žãã©ã€ããçšããŠè¡ãªããããäžè¬åŒ
ïŒ1aïŒã®ååç©ã«å¯Ÿããå¡©åºåã³ã¢ã·ã«åå€ã®äœ¿
çšå²åã¯ãé©å®ã«éžæã§ããããéåžžå¡©åºãçŽïŒ
ã100ååœéåã³ã¢ã·ã«åå€ãçŽïŒã10ååœéã®
ç¯å²ã§çšããã®ããããåå¿ã¯çŽïŒã30âã®æž©åºŠ
æ¡ä»¶äžã«ãçŽïŒã20æéãèŠããŠè¡ãªããããã
ã«ããäžè¬åŒïŒ1bïŒã§è¡šããããæ¬çºæååç©
ãååŸã§ããã
äžèšåè¡çšã§åŸãããç®çç©ã¯ãæ
£çšã®å颿
段ãäŸãã°æº¶åªæœåºãåçµæ¶ãã«ã©ã ã¯ãããã°
ã©ãã€ãŒçã«ãã容æã«åé¢ç²Ÿè£œããããšãã§ã
ãã
ãåŒäžR1ãR4åã³R5ã¯åèšã«åããã
äžèšåå¿è¡çšåŒâïŒã«ããã°ãäžè¬åŒ(2)ã®ã¢ã«
ããããã¢ã«ã«ãªéå±ã·ã¢ã³åç©ãšåå¿ãããŠã
äžè¬åŒ(5)ã®ã·ã¢ã³ãããªã³ååç©ãšããåŸããã
ãéå
ãã¢ã«ãã«ååå¿ãããããšã«ãããäžè¬
åŒ(1)äžR2ãæ°Žé
žåºã§ããæ¬çºæååç©ãååŸã§
ããã
äžè¬åŒ(2)ã®ã¢ã«ããããšã¢ã«ã«ãªéå±ã·ã¢ã³å
ç©ãšã®åå¿ã¯ãéåžžã®æ¹æ³ãäŸãã°äºç¡«é
žæ°ŽçŽ ã
ããªãŠã å¡©ãçµãæ¹æ³ã«åŸã宿œã§ãããW.
Revue et al.ïŒJ.Am.Chem.Soc.ïŒ79ïŒ1932
ïŒ1957ïŒããå³ã¡äžè¬åŒ(2)ã®ã¢ã«ããããããšãŒã
ã«ãããã©ããããã©ã³ããžãªããµã³çã«æžæ¿å
ã¯æº¶è§£ãããæ°·å·äžã«ãŠè©²ã¢ã«ãããã«å¯ŸããŠïŒ
ãïŒåã¢ã«çšåºŠã®äºç¡«é
žæ°ŽçŽ ãããªãŠã 氎溶液ã
å ãã30åãïŒæéæ¹æãç¶ããããã®åŸæåºã
ãçµæ¶ãåãããæŽã«åŸãããçµæ¶ãæ°Žã«æžæ¿
ãããïŒãïŒåã¢ã«çšåºŠã®ã¢ã«ã«ãªéå±ã·ã¢ã³å
ç©ã®æ°Žæº¶æ¶²ãå ãããæ¹æãïŒãïŒæéç¶ãã
åŸãæåºããçµæ¶ãåãã也ç¥ãããããããŠ
äžè¬åŒ(5)ã®ã·ã¢ã³ãããªã³ååç©ãåŸããããã¯
æç®æªèŒã®æ°èŠååç©ã§ãããæ¬çºæã®ïŒïŒïŒïŒ
ïŒïŒïŒâããã©ã¢ã«ã³ãã·ããã¿ã¬ã³èªå°äœã®å
æäžéäœãšããŠéèŠãªãã®ã§ããã
äžèšã·ã¢ã³ãããªã³ååç©(5)ã®éå
åå¿ã¯ãé
åžžã®æ¹æ³ã«åŸããé©åœãªéå
å€ãäŸãã°LiAlH4
ãããã©ãžãŠã âççŽ ç³»è§Šåªççšããæ¥è§Šæ°Žæ·»ã
é
¢é
žãããªãã«ãªãé
¢é
žçã®ææ©é
žãå ããŠ
NaBH4çãçšããæ¹æ³çã«ããè¡ãªãããšãã§
ãããç¹ã«è©Šè¬ã®çšãæãã倧éåæã®å¯èœæ§ã
èæ
®ããã°ããªãã«ãªãé
¢é
žâNaBH4ç³»ãçšã
ãæ¹æ³ãN.Umino et al.ïŒTetrahedron Lett.ïŒ
33ïŒ2875ïŒ1977ïŒãã奜ãŸãããè©²æ¹æ³ã¯ãã詳现
ã«ã¯ããšãŒãã«ãããã©ããããã©ã³ããžãªããµ
ã³çã®æº¶åªã奜ãŸããã¯ããã©ããããã©ã³äž
ã«ãã·ã¢ã³ãããªã³ååç©(5)ã«å¯ŸããŠçŽïŒãïŒå
ã¢ã«ã奜ãŸããã¯çŽïŒåã¢ã«éã®NaBH4ãæžæ¿
ãããããã«æ°·å·äžã«ã·ã¢ã³ãããªã³ååç©(5)ã«
察ããŠçŽïŒåã¢ã«éã®ããªãã«ãªãé
¢é
žãå ãã
次ãã§äžèšæ··æ¶²äžã«ã·ã¢ã³ãããªã³ååç©(5)ã®ã
ãã©ããããã©ã³æº¶æ¶²ãå ããçŽïŒã50âã奜ãŸ
ããã¯ïŒã20âçšåºŠã®æž©åºŠäžã«éåžžçŽïŒã10æé
ãèŠããŠå®æœããããããããŠäžè¬åŒïŒ1cïŒã®å
åç©ãåŸãã
äžèšéå
åå¿ã«ããåŸãããäžè¬åŒïŒ1cïŒã®å
åç©ã®ã¢ã«ãã«ååå¿ã¯ãéåžžã®æ¹æ³ãäŸãã°é©
åœãªæº¶åªäžã§è±é
žå€åã³ã¢ã«ãã«åå€ãçšããŠè¡
ãªããããè±é
žå€ãšããŠã¯äžè¬ã«çšããããåçš®
ã®ãã®ãäŸãã°ããªãšãã«ã¢ãã³ãããªãžã³çã®
ææ©ã¢ãã³é¡ãçé
žã«ãªãŠã ãçé
žãããªãŠã ç
ãå©çšã§ãããã¢ã«ãã«åå€ãšããŠã¯éåžžã®ãã
ã²ã³åã¢ã«ãã«ãäŸãã°ãšãŠåã¡ãã«ããšãã«ã
ããã€ãããã³ãžã«ã¯ãã©ã€ããããšããã«ãã
ãã€ããã·ã¯ãããã·ã«ã¯ãã©ã€ãçãå©çšã§ã
ãããŸã溶åªãšããŠã¯ïŒ®ïŒïŒ®âãžã¡ãã«ãã«ã ã¢
ããããžã¡ãã«ã¹ã«ããã·ãããªã³é
žãããµã¡ã
ã«ããªã¢ãããããã©ããããã©ã³ãã¢ã»ãã³ç
ã®æ¥µæ§æº¶åªã奜é©ã«çšããããšãã§ãããè±é
žå€
åã³ã¢ã«ãã«åå€ã®äœ¿çšéã¯ãç¹ã«å¶éã¯ãªã
ããéåžžäžè¬åŒïŒ1cïŒã®ååç©ã«å¯ŸããŠãè±é
žå€
ã¯çã¢ã«ãïŒåã¢ã«çšåºŠãããã²ã³åã¢ã«ãã«ã¯
çã¢ã«ãïŒåã¢ã«çšåºŠã®ç¯å²ãšãããã®ãããã
åå¿ã¯äžè¬ã«å®€æž©ä»è¿ã§é²è¡ããçŽïŒã48æéã§
å®çµããããŸãäžèšã¢ã«ãã«ååå¿ã¯ãéå
çã¢
ã«ãã«åãšåŒã°ããéåžžã®æ¹æ³ã«ãã€ãŠã宿œã
ãããšãã§ããããã®æ¹æ³ã¯äžè¬åŒïŒ1cïŒã®åå
ç©ïŒã¢ãã³ïŒãšä»»æã®ã±ãã³åã¯ã¢ã«ããããšã®
ã·ããå¡©åºãéå
ããããšã«ããè¡ãªããããã±
ãã³åã³ã¢ã«ããããšããŠã¯ãäŸãã°ã¢ã»ãã³ã
ã·ã¯ããããµãã³ãã¢ã»ãããšãã³ããã³ãºã¢ã«
ããããïŒâãã¿ãã³ãã¢ãã¹ã¢ã«ãããçãäŸ
瀺ã§ãããä¹çã¯éåžžäžè¬åŒïŒ1cïŒã®ã¢ãã³ã«å¯Ÿ
ããŠçã¢ã«ã10åã¢ã«ã奜ãŸããã¯çŽïŒåã¢ã«å
åŸã®éã§çšãããããåå¿ã¯ã¡ã¿ããŒã«ããšã¿ã
ãŒã«ããžã¡ãã«ãã«ã ã¢ããâãšã¿ããŒã«ããžã¡
ãã«ãã«ã ã¢ããâã¡ã¿ããŒã«æ··å溶åªçã®é©åœ
ãªæº¶åªäžã«äžè¬åŒïŒ1cïŒã®ã¢ãã³åã³ã±ãã³åã¯
ã¢ã«ããããå ãããã®æ··åç©äžã«æ°·å·äžã«éå
å€äŸãã°NaBH4ãNaBH3CNçã®çã¢ã«ãïŒå
ã¢ã«éã奜ãŸããã¯çã¢ã«ãïŒåã¢ã«éïŒäžè¬åŒ
ïŒ1cïŒã®ååç©ã«å¯ŸããïŒãå ããããšã«ããçŽ
30åã20æéçšåºŠã§çµäºããããŸãäžè𿹿³ã¯ã
ä»ã«ãã©ãžãŠã âççŽ ç³»è§Šåªãçšããæ¥è§Šæ°Žæ·»ã«
ãã€ãŠãè¡ãªãåŸãããã®å Žåãäžèšæº¶åªã«æº¶è§£
ããäžè¬åŒïŒ1cïŒã®ååç©ãšã±ãã³åã¯ã¢ã«ãã
ããšã®æ··åç©ã«ãåžžå§ãïŒæ°å§ã®å§åäžã宀枩ã
50âçšåºŠã®æž©åºŠæ¡ä»¶äžã«æ°ŽçŽ æ·»å ãè¡ãªãã®ã奜
ãŸãããããããŠäžè¬åŒïŒ1dïŒã®æ¬çºæååç©
ãåŸãã
ãŸãäžè¬åŒ(1)äžR2ãäœçŽã¢ã«ã«ãã€ã«ãªãã·
åºã§ããæ¬çºæååç©ã¯ãäžèšåå¿è¡çšåŒâïŒã«
ç€ºãæ¹æ³ã«ããåŸãããäžè¬åŒïŒ1dïŒã®ååç©
ã«ãåèšåå¿è¡çšåŒâïŒã«ç€ºãäžè¬åŒïŒ1aïŒã®
ååç©ã®ã¢ã·ã«ååå¿ãšåæ§ã®åå¿ãé©çšããã
ãšã«ãã€ãŠã補é ããããšãã§ããã
äžèšååå¿è¡çšã«ããåŸãããååç©ã¯ãæ
£çš
ã®åé¢ææ®µãäŸãã°æº¶åªæœåºãåçµæ¶ãã«ã©ã ã¯
ãããã°ã©ãã€ãŒçã«ãã容æã«åé¢ç²Ÿè£œããã
ãšãã§ããã
æ¬çºæã®åèšäžè¬åŒ(1)ã§è¡šããããååç©ã¯ã
ããã«é©åœãªç¡æ©ãããã¯ææ©é
žãåå¿ãããã
ãšã«ãããè¬ççã«èš±å®¹ãããé
žä»å å¡©ãšããã
ãšãã§ããæ¬çºæã¯ãããå¡©ããå
å«ãããäžèš
å¡©ã®åœ¢æåå¿ã¯åžžæ³ã«åŸãããšãã§ãããã®éçš
ããããé
žãéåžžã®ãã®ã§ããããã®å
·äœäŸãšã
ãŠã¯äŸãã°ç¡«é
žãå¡©é
žãç¡é
žçã®ç¡æ©é
žåã³ã·ãŠ
ãŠé
žããã¬ã€ã³é
žãããã«é
žãã¯ãšã³é
žçã®ææ©
é
žãäŸç€ºã§ãããæŽã«æ¬çºæååç©ã«ã¯å
åŠç°æ§
äœãèããããæ¬çºæã¯ãããç°æ§äœããåœç¶ã«
å
å«ããã
以äžãæ¬çºæååç©ã®è£œé ã«å©çšããäžè¬åŒ(3)
ã®ãšããã·ãåã³äžè¬åŒ(5)ã®ã·ã¢ã³ãããªã³åå
ç©ã®è£œé äŸãåèäŸãšããŠæããæ¬¡ãã§æ¬çºæå
åç©ã®è£œé äŸãæããã
åèäŸ ïŒ
ïŒâïŒïŒïŒïŒâãšããã·ãšãã«ïŒâïŒïŒïŒïŒïŒïŒ
ïŒâããã©ã¡ããã·ããã¿ã¬ã³ãäžè¬åŒ(3)ã
R1ïŒOCH3ãã®è£œé
ïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ããã·âïŒâããã¿
ã¬ã³ã«ã«ãã¢ã«ããã5.6ïœïŒ20mMïŒãããªã¡ã
ã«ã¹ã«ãããŠã ãšãŒãã€ã4.3ïœïŒ21mMïŒåã³
ããã©âïœâããã«ã¢ã³ã¢ããŠã ãšãŒãã€ã140
mgããå¡©åã¡ãã¬ã³100mlåã³50ïŒ
æ°Žé
žåãããª
ãŠã 溶液80mlã«æº¶è§£ããæ¹æäžã«50âã§24æéå
ç±ããåå¿ããããåå¿çµäºåŸãææ©å±€ãåå
ããä¹Ÿç¥æ¿çž®ããŠæ·¡é»è²çµæ¶5.6ïœãåŸãããã®
ãã®ã¯ãšãŒãã«ïŒïœâãããµã³æ··å溶åªããåçµ
æ¶ããããšãã§ããã
èç¹ 84ã85âïŒåçµæ¶åŸïŒ
1HâNMRïŒCDCl3ãTMSãppmïŒ
ÎŽïŒ6.83ïŒïœïŒ2HïŒã6.62ïŒïœïŒ2HïŒã3.94ïŒïœïŒ
3HïŒã3.91ïŒïœïŒ3HïŒã3.88ïŒïœïŒ3HïŒã3.82ïŒïœïŒ
3HïŒã4.43ïŒddïŒ4.4ïŒ2.6ïŒ1HïŒã3.22ïŒddïŒ5.7ïŒ
4.4ïŒ1HïŒã2.78ïŒddïŒ5.7ïŒ2.6ïŒ1HïŒ
åèäŸ ïŒ
αâããããã·âïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ã
ãã·ããã¿ã¬ã³âïŒâã¢ã»ããããªã«ãäžè¬åŒ
(5)ãR1ïŒOCH3ãã®è£œé
ïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ããã·âïŒâããã¿
ã¬ã³ã«ã«ãã¢ã«ããã2.4ïœã®ããã©ããããã©
ã³10ml溶液ã«ãäºç¡«é
žæ°ŽçŽ ãããªãŠã 2.1ïœã®æ°Ž
ïŒml溶液ã宀枩ã§å ãã30åæ¹æãããåå¿æº¶æ¶²
ã«æ°·å·äžãšãã«ãšãŒãã«60mlãå ããæåºããçµ
æ¶ãåããã€ãœãããããŒã«ã§æŽæµãããåŸã
ããçµæ¶ãæ°Ž30mlã«æžæ¿ããã·ã¢ã³åãããªãŠã
ïŒïœã®æ°ŽïŒml溶液ãå ãã30åéæ¹æåŸãçæã
ãçµæ¶ãåããŠç®çç©ïŒïœãåŸãã
èç¹ 110ã116â
1HâNMRïŒCDCl3ãTMSãppmïŒ
ÎŽïŒ6.87ïŒïœïŒ3HïŒã5.87ïŒïœïŒ7.3ïŒ1HïŒã4.12
ïŒïœïŒ7.3ïŒ1HïŒã3.94ïŒïœïŒ3HïŒã3.89ïŒïœïŒ
6HïŒã3.85ïŒïœïŒ3HïŒ
宿œäŸ ïŒ
ããªãã«ãªãé
¢é
ž3.1ïœã®ããã©ããããã©ã³
ïŒml溶液ããæ°ŽçŽ åããŠçŽ ãããªãŠã ïŒïœã®ãã
ã©ããããã©ã³20ml溶液äžã«ã20â以äžã§å ã
ãããã®æ··åç©äžã«ãåèäŸïŒã§åŸãαâããã
ãã·âïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ããã·ããã¿ã¬
ã³âïŒâã¢ã»ããããªã«1.65ïœïŒ5.4mMïŒã®ãã
ã©ããããã©ã³10ml溶液ã20â以äžã§å ãããã®
åŸå®€æž©ã§ïŒæéæ¹æãç¶ãããåå¿æ··åç©ãæ°Žã«
ç§»ããå¡©åã¡ãã¬ã³ã§æœåºããææ©å±€ã也ç¥ãæ¿
çž®åŸãã·ãªã«ã²ã«ã«ã©ã ã¯ãããã°ã©ãã€ãŒïŒã¡
ã¿ããŒã«ïŒã¯ãããã«ã ïŒã§ç²Ÿè£œããŠãαâã¢ã
ãã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ããã·ãã
ã¿ã¬ã³âïŒâã¡ã¿ããŒã«ã®500mgãæ²¹ç¶ç©ãšããŠ
åŸãã
åŸãããååç©ã®æ§é åã³ç©æ§ã第ïŒè¡šã«ç€º
ãã
宿œäŸ ïŒ
αâã¢ããã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâããã©ã¡
ããã·ããã¿ã¬ã³âïŒâã¡ã¿ããŒã«310mg
ïŒ1mMïŒåã³ã¢ã»ãã³300mgã®ã¡ã¿ããŒã«ïŒml溶
æ¶²ã«æ°·å·äžNaBH3CN65mgããã€ããå ããã
ãã®åŸã宀枩ã«åŸã
ã«ãã©ã16æéæ¹æãç¶ã
ããåå¿æ¶²ãæ°Žã«ç§»ããã¯ãããã«ã ã§æœåºãã
ææ©å±€ã也ç¥åŸãæ¿çž®ããŠåŸãããç²çæç©ãã·
ãªã«ã²ã«ã¯ãããã°ã©ãã€ãŒïŒã¯ãããã«ã ïŒã¡
ã¿ããŒã«ïŒ20ïŒ1VïŒïŒ¶ïŒã§ç²Ÿè£œããŠÎ±âïŒïŒâã¡
ãã«ãšãã«ïŒã¢ããã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâã
ãã©ã¡ããã·ããã¿ã¬ã³âïŒâã¡ã¿ããŒã«272mg
ïŒåç78ïŒ
ïŒãåŸããååç©ã®æ§é åã³ç©æ§ã第
ïŒè¡šã«ç€ºãã
宿œäŸ ïŒãïŒ
äžèšå®æœäŸïŒåã³ïŒãšåæ§ã«ããŠã第ïŒè¡šã«ç€º
ã宿œäŸïŒãïŒã®åååç©ãåŸãããŸãä¹çåå
åç©ã¯ãåŸè¿°ãã宿œäŸ13ã«èšèŒã®æ¹æ³ã«åŸã€ãŠ
ã補é ãããã
宿œäŸ 10
αâãããªãžãã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâãã
ã©ã¡ããã·ããã¿ã¬ã³âïŒâã¡ã¿ããŒã«750mgã
ããªãžã³ïŒmlã«æº¶è§£ããç¡æ°Žé
¢é
žïŒmlãå ãã25
âã§ïŒæéæ¹æãããæ°Žã«ç§»ãé
¢é
žãšãã«ã§æœåº
ãææ©å±€ãæ°ŽæŽãããææ©å±€ãæ¿çž®åŸãåŸããã
ç²çæç©ãã·ãªã«ã²ã«ã¯ãããã°ã©ãã€ãŒïŒã¡ã¿
ããŒã«ïŒã¯ãããã«ã 1/30ïŒïŒ¶ïŒã§ç²Ÿè£œãããš
740mgïŒ88ïŒ
ïŒã®ïŒâïŒïŒâã¢ã»ããã·âïŒâãã
ãªãžããšãã«ïŒâïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ãã
ã·ããã¿ã¬ã³ãæ²¹ç¶ç©è³ªãšããŠåŸãããã®æ§é å
ã³ç©æ§ã第ïŒè¡šã«ç€ºãã
宿œäŸ 11åã³12
äžèšå®æœäŸ10ãšåæ§ã«ããŠäžèšç¬¬ïŒè¡šã«ç€ºãå®
æœäŸ11åã³12ã®ååç©ãåŸãã
ã衚ã
ã衚ã
ã衚ã
宿œäŸ 13
åèäŸïŒã§åŸãïŒâïŒïŒïŒïŒâãšããã·ãšãã«ïŒ
âïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ããã·ããã¿ã¬ã³ïŒ
ïœãšãã€ãœãããã«ã¢ãã³ïŒïœãšãã¡ã¿ããŒã«60
mlã«æº¶è§£ããïŒæ¥éå®€æž©ã§æ¹æããããã®åŸã¡ã¿
ããŒã«ãçå»ããåŸãããæ²¹ç¶ç©è³ªãã·ãªã«ã²ã«
ã«ã©ã ã¯ãããã°ã©ãã€ãŒïŒã¯ãããã«ã ïŒã¡ã¿
ããŒã«ïŒ30/1ïŒïŒ¶ïŒã§ç²Ÿè£œããŠ360mgïŒåçïŒ
ïŒ
ïŒã®Î²âïŒïŒâã¡ãã«ãšãã«ïŒã¢ããâïŒïŒïŒïŒ
ïŒïŒïŒâããã©ã¡ããã·ããã¿ã¬ã³âïŒâãšã¿ã
ãŒã«ãæ²¹ç¶ç©è³ªãšããŠåŸãããã®ãã®ã¯ããšã¿ã
ãŒã«ã«æº¶è§£åŸã也ç¥ããå¡©é
žã§é
žæ§ãšãããšãŒã
ã«ãå ããããšã«ããçµæ¶ãšããŠåããããšã
ã§ãããã®ç©æ§ã¯åèšå®æœäŸïŒã§åŸãååç©ã®ã
ããšäžèŽããã
ãŸãäžèšã·ãªã«ã²ã«ã«ã©ã ã¯ãããã°ã©ãã€ãŒ
ã«ãããŠãããã«ã¯ãããã«ã ïŒã¡ã¿ããŒã«ïŒ2
ïŒïŒïŒïŒïŒ¶ïŒïŒ¶æ¯ïŒã§å±éãç¶ããããšã«ããã400
mgïŒåç33ïŒ
ïŒã®Î±âïŒïŒâã¡ãã«ãšãã«ïŒã¢ã
ãã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâããã©ã¡ããã·ãã
ã¿ã¬ã³âïŒâã¡ã¿ããŒã«ãæ²¹ç¶ç©è³ªãšããŠåŸãã
ãã®æ²¹ç¶ç©è³ªã¯ããšã¿ããŒã«ã«æº¶è§£ãã也ç¥ãã
å¡©é
žã§é
žæ§ãšããåŸã«ããšãŒãã«ãå ããŠçµæ¶ãš
ããŠåããããšãã§ããããã®ååç©ã®æ§é å
ã³ç©æ§ã宿œäŸNo.13ãšããŠç¬¬ïŒè¡šã«ç€ºãã
宿œäŸ 14ã21
宿œäŸ13ãšåæ§ã«ããŠãåèšå®æœäŸïŒãïŒã«ç€º
ãåååç©ãšå
±ã«ãåŸèšç¬¬ïŒè¡šã«ç€ºã宿œäŸ14ã
21ã®åååç©ãåŸãã
宿œäŸ 22ã24
åèšå®æœäŸ10ãšåæ§ã®æäœãè¡ãªã€ãŠãäžèšç¬¬
ïŒè¡šã«ç€ºã宿œäŸ22ã24ã®åååç©ãåŸãã
ã衚ã
ã衚ã DETAILED DESCRIPTION OF THE INVENTION The present invention relates to 1,4,5,8-tetraalkoxynaphthalene derivatives and salts thereof. The above-mentioned derivative of the present invention is a novel compound that has not been described in any literature, and is represented by the following general formula (1). [In the formula, R 1 represents a lower alkoxy group. R 2 and
One of R 3 represents a hydroxyl group or a lower alkanoyloxy group, and the other represents a group [Formula]. In this group, R 4 and R 5 are the same or different and are hydrogen atoms,
A lower alkyl group, a cycloalkyl group, a phenyl group that may have a lower alkoxy group as a substituent on the phenyl ring, or a phenyl lower alkyl group that may have a lower alkoxy group as a substituent on the phenyl ring. Furthermore, R 4 and R 5 may be bonded to each other with or without an oxygen atom or a nitrogen atom to form a heterocyclic group together with the adjacent nitrogen atom, and the heterocyclic group may further include a phenyl lower alkyl group. It may be included as a substituent. ] In the above general formula (1), examples of the lower alkoxy group defined by R 1 include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy groups. Examples of lower alkanoyloxy groups defined for R 2 and R 3 include acetoxy, propionyloxy, butyryloxy, isobutyryloxy,
Examples include valeryloxy and isovaleryloxy groups. Examples of lower alkyl groups represented by R 4 and R 5 forming the group [formula] include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl groups, etc. represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups, and phenyl groups which may have a lower alkoxy group as a substituent on the phenyl ring include, for example, phenyl, 1
-methoxyphenyl, 2-methoxyphenyl, 3
-butoxyphenyl, 2-methoxy-3-ethoxyphenyl, 3,4-dimethoxyphenyl, 2,
4-dipropoxyphenyl, 3,4,5-trimethoxyphenyl, 2,4,6-triethoxyphenyl groups, etc., and phenyl lower which may further have a lower alkoxy group as a substituent on the phenyl ring. Examples of the alkyl group include benzyl, α-phenethyl, β-phenethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, 1-phenylbutyl, 2-phenylbutyl,
3-phenylbutyl, 4-phenylbutyl, 1-
Phenylpentyl, 3-phenylpentyl, 5-
Phenylpentyl, 1-phenylhexyl, 3-
Phenylhexyl, 5-phenylhexyl, 1,
Unsubstituted phenylalkyl groups such as 1-dimethyl-2-phenylethyl and e.g. 2-methoxybenzyl, 3-ethoxy-β-phenethyl, 4-propoxy-β-phenethyl, 1-(2,3-dimethoxyphenyl) ) propyl, 1-(3,4-diethoxyphenyl)butyl, 3,4,5-trimethoxybenzyl, 3,4-dimethoxy-β-phenethyl, 4-(2,3-dimethoxyphenyl)hexyl group Examples of substituted phenylalkyl groups include the following. Furthermore, examples of the heterocyclic group that can be formed by the above group [formula] include 1-pyrrolidinyl, piperidino,
Examples include piperazinyl and morpholino groups, and the above-mentioned heterocyclic groups substituted with phenyl lower alkyl include:
A piperazinyl group substituted with the above unsubstituted phenylalkyl group, for example, N-benzylpiperazinyl,
Examples include N-α-phenethylpiperazinyl and N-β-phenethylpiperazinyl groups. The derivatives of the present invention represented by the above general formula (1) and their salts, that is, addition salts of inorganic or organic acids, all have therapeutic and preventive effects on heart diseases and hypertension such as instinctive hypertension, etc. It is useful as a drug that utilizes the pharmacological action of, for example, as a therapeutic or preventive agent for congestive heart failure, angina pectoris, myocardial infarction, hypertension, cardiac arrhythmia, hyperkinetic heart syndrome, etc. The derivatives of the present invention can be produced by various methods. Preferred specific examples thereof are shown in the following reaction scheme and will be described in detail. [In the formula, R 1 , R 4 and R 5 are the same as above. R 2 Ⲡand
One of R 3 ' is a hydroxyl group and the other is a group (R 4 and R 5 are the same as above). Further, R 2 â³ and R 3 â³ represent a lower alkanoyloxy group on one side and a group on the other hand (R 4 and R 5 are the same as above). ] According to Reaction Scheme-1, the amine of the general formula (4) is reacted with the epoxide of the general formula (3) obtained by converting a known aldehyde represented by the general formula (2) into an epoxy form. According to general formula (1), R 2 and R 3
The compound of the present invention (1a) in which one of R 2 and R 3 in the general formula (1) is a lower alkanoyloxy group can be obtained by subjecting the compound (1a) to an acylation reaction. Compound (1b)
can be obtained. The epoxidation reaction of the aldehyde of general formula (2) in the above can be carried out by a known method, such as Merkl (G.
[Angew.Chem., 85 , 867]
(1973)]. That is, about 1 to 5 mole % of a phase transfer catalyst, such as benzyltriethylammonium chloride, tetra-n-
In the presence of a quaternary ammonium salt such as butylammonium iodide, in a two-phase system of 50% alkali hydroxide and dichloromethane, aldehyde of general formula (2),
This is carried out by reacting with trimethylsulfonium iodide in an amount of about 1 to 1.3 times the molar amount. The reaction is carried out at a temperature of about 50°C.
The process is usually completed within 24 to 48 hours, thereby obtaining the epoxide of general formula (3). The epoxide (3) is a new compound that has not been described in any literature, and is important as a synthetic intermediate for the 1,4,5,8-tetraalkoxynaphthalene derivative of the present invention. The reaction between the epoxide (3) and the known amine represented by the general formula (4) is usually carried out in a suitable solvent. Various solvents can be used that do not adversely affect the reaction, and alcoholic solvents such as methanol, ethanol, isopropanol, tert-butanol, and isoamyl alcohol are particularly suitable. The ratio of amine (4) to epoxide (3) is not particularly limited, but is usually at least an equivalent, generally about 1 to 20 times the equivalent. The reaction is approx.
Under temperature conditions ranging from 25°C to the boiling point of the solvent, usually about 5
It will be done in hours to 10 days. This reaction yields the compound of the present invention represented by general formula (1a). This is usually a mixture of a compound in which R 2 â² is a hydroxyl group in general formula (1a) and a compound in which R 3 â² is a hydroxyl group, and generally, the epoxide of general formula (3) used as a raw material is formed into a naphthalene ring. Since it has an alkoxy group (R 1 ) which is an electron-donating group, compounds in which R 3 ' is a hydroxyl group are often obtained as the main product. Such mixtures can be separated according to conventional methods. The acylation reaction of the compound of general formula (1a) subsequent to the above reaction is performed using an acylating agent such as a lower alkyl carboxylic acid anhydride or acid halide in the presence of a base such as pyridine, triethylamine, etc., in accordance with a conventional method. It is done. The ratio of the base and acylating agent to the compound of general formula (1a) can be selected as appropriate, but usually the base is
-100 times equivalent and the acylating agent is preferably used in a range of about 1 to 10 times equivalent. The reaction is carried out at a temperature of about 0 to 30° C. for about 1 to 20 hours, whereby the compound of the present invention represented by general formula (1b) can be obtained. The target products obtained in each of the above steps can be easily isolated and purified by conventional separation means such as solvent extraction, recrystallization, column chromatography, etc. [In the formula, R 1 , R 4 and R 5 are the same as above. ] According to the reaction scheme-2 above, the aldehyde of general formula (2) is reacted with an alkali metal cyanide,
The compound of the present invention in which R 2 in the general formula (1) is a hydroxyl group can be obtained by converting the cyanohydrin compound of the general formula (5) into a cyanohydrin compound and then subjecting it to a reduction and alkylation reaction. The reaction between the aldehyde of general formula (2) and the alkali metal cyanide can be carried out according to a conventional method, for example, a method involving sodium bisulfite [W.
Revue et al., J.Am.Chem.Soc., 79 , 1932
(1957)]. That is, the aldehyde of general formula (2) is suspended or dissolved in ether, tetrahydrofuran, dioxane, etc., and 2
Add about 3 times the mole of sodium bisulfite aqueous solution and continue stirring for 30 minutes to 2 hours. Then, collect the precipitated crystals. Further, the obtained crystals are suspended in water, and an aqueous solution of alkali metal cyanide in an amount of about 2 to 3 times the mole is added. After stirring for 1 to 2 hours, the precipitated crystals are collected and dried. In this way, a cyanohydrin compound of general formula (5) is obtained. This is a new compound that has not been described in any literature, and 1, 4, and 1 of the present invention.
It is important as a synthetic intermediate for 5,8-tetraalkoxynaphthalene derivatives. The reduction reaction of the above cyanohydrin compound (5) is carried out using a suitable reducing agent such as LiAlH 4 according to a conventional method.
By catalytic hydrogenation using a palladium-carbon catalyst or by adding an organic acid such as acetic acid or trifluoroacetic acid,
This can be carried out by a method using NaBH 4 or the like. In particular, considering the ease of use of reagents and the possibility of mass synthesis, there is a method using trifluoroacetic acid-NaBH 4 system [N. Umino et al., Tetrahedron Lett.,
33, 2875 (1977)] is preferred. More specifically, the method involves suspending NaBH 4 in a molar amount of about 4 to 8 times, preferably about 5 times, relative to the cyanohydrin compound (5) in a solvent such as ether, tetrahydrofuran, dioxane, etc., preferably tetrahydrofuran. To this, add about 5 times the molar amount of trifluoroacetic acid to the cyanohydrin compound (5) under ice-cooling.
Next, a solution of the cyanohydrin compound (5) in tetrahydrofuran is added to the above mixed liquid, and the reaction is carried out at a temperature of about 0 to 50°C, preferably about 0 to 20°C, usually taking about 2 to 10 hours. Thus, a compound of general formula (1c) is obtained. The alkylation reaction of the compound of general formula (1c) obtained by the above reduction reaction is carried out by a conventional method, for example, using a deoxidizing agent and an alkylating agent in a suitable solvent. Various commonly used deoxidizing agents can be used, such as organic amines such as triethylamine and pyridine, potassium carbonate, and sodium carbonate. As the alkylating agent, common alkyl halides such as methyl iodide, ethyl bromide, benzyl chloride, phenethyl bromide, cyclohexyl chloride, etc. can be used. As the solvent, polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, hexamethyltriamide phosphate, tetrahydrofuran, and acetone can be suitably used. The amount of the deoxidizing agent and alkylating agent to be used is not particularly limited, but the amount of the deoxidizing agent is usually about 1 to 5 times the mole of the compound of general formula (1c), and the amount of the alkyl halide is about 1 to 6 times the mole of the compound of general formula (1c). It is preferable to set it in a range of about twice the molar amount.
The reaction generally proceeds around room temperature and is complete in about 5 to 48 hours. Further, the above alkylation reaction can also be carried out by a conventional method called reductive alkylation. This method is carried out by reducing the Schiff base of the compound of general formula (1c) (amine) and any ketone or aldehyde. Ketones and aldehydes include, for example, acetone,
Examples include cyclohexanone, acetophenone, benzaldehyde, 2-butanone, and anisaldehyde. These are usually used in an amount of equimolar to 10 times the amine of general formula (1c), preferably about 5 times the molar amount. The reaction is carried out by adding the amine of general formula (1c) and a ketone or aldehyde to a suitable solvent such as methanol, ethanol, dimethylformamide-ethanol, dimethylformamide-methanol mixed solvent, etc., and adding a reducing agent such as NaBH to this mixture under ice cooling. 4 , NaBH 3 CN, etc. in an equimolar to 5-fold molar amount, preferably in an equimolar to 2-fold molar amount (relative to the compound of general formula (1c)).
It takes about 30 minutes to 20 hours to complete. In addition, the above method
Alternatively, catalytic hydrogenation using a palladium-carbon catalyst may also be used. In this case, a mixture of the compound of general formula (1c) and a ketone or aldehyde dissolved in the above-mentioned solvent is added at room temperature to
It is preferable to perform hydrogenation at a temperature of about 50°C. In this way, the compound of the present invention of general formula (1d) is obtained. Further, the compound of the present invention in which R 2 in the general formula (1) is a lower alkanoyloxy group can be added to the compound of the general formula (1d) obtained by the method shown in the above reaction scheme-2, as shown in the above reaction scheme-1. It can also be produced by applying a reaction similar to the acylation reaction of the compound of general formula (1a). The compounds obtained by each of the above reaction steps can be easily isolated and purified by conventional separation means such as solvent extraction, recrystallization, column chromatography, etc. The compound represented by the general formula (1) of the present invention is:
By reacting this with a suitable inorganic or organic acid, a pharmacologically acceptable acid addition salt can be obtained, and the present invention also includes such a salt. The above-mentioned salt formation reaction can be carried out in accordance with a conventional method, and the acid used at that time may also be a conventional one. Specific examples include inorganic acids such as sulfuric acid, hydrochloric acid, and nitric acid, and organic acids such as oxalic acid, maleic acid, fumaric acid, and citric acid. Further, the compounds of the present invention may have optical isomers, and the present invention naturally includes such isomers. Below, general formula (3) used for the production of the compound of the present invention
Examples of the production of the epoxide and the cyanohydrin compound of general formula (5) will be listed as reference examples, and then production examples of the compounds of the present invention will be listed. Reference example 1 2-(1,2-epoxyethyl)-1,4,5,
8-tetramethoxynaphthalene [general formula (3),
1,4,5,8 -tetramethoxy-2-naphthalenecarbaldehyde 5.6g ( 20mM ), trimethylsulfonium iodide 4.3g (21mM) and tetra-n-butylammonium iodide 140
mg is dissolved in 100 ml of methylene chloride and 80 ml of 50% sodium hydroxide solution and heated under stirring at 50° C. for 24 hours to react. After the reaction is completed, the organic layer is separated, dried and concentrated to obtain 5.6 g of pale yellow crystals. This product can be recrystallized from a mixed solvent of ether/n-hexane. Melting point 84-85â (after recrystallization) 1 H-NMR (CDCl 3 , TMS, ppm) ÎŽ = 6.83 (s, 2H), 6.62 (s, 2H), 3.94 (s,
3H), 3.91 (s, 3H), 3.88 (s, 3H), 3.82 (s,
3H), 4.43 (dd, 4.4, 2.6, 1H), 3.22 (dd, 5.7,
4.4, 1H), 2.78 (dd, 5.7, 2.6, 1H) Reference example 2 α-hydroxy-1,4,5,8-tetramethoxynaphthalene-2-acetonitrile [general formula
(5), R 1 = OCH 3 ] To a solution of 2.4 g of 1,4,5,8-tetramethoxy-2-naphthalenecarbaldehyde in 10 ml of tetrahydrofuran, a solution of 2.1 g of sodium bisulfite in 6 ml of water was added at room temperature. Stir for 30 minutes. Add 60 ml of ethyl ether to the reaction solution under ice cooling, collect the precipitated crystals, and wash with isopropanol. The resulting crystals are suspended in 30 ml of water, a solution of 1 g of sodium cyanide in 4 ml of water is added, and after stirring for 30 minutes, the resulting crystals are collected to obtain 2 g of the desired product. Melting point 110-116â 1 H-NMR (CDCl 3 , TMS, ppm) ÎŽ = 6.87 (s, 3H), 5.87 (d, 7.3, 1H), 4.12
(d, 7.3, 1H), 3.94 (s, 3H), 3.89 (s,
6H), 3.85 (s, 3H) Example 1 A solution of 3.1 g of trifluoroacetic acid in 2 ml of tetrahydrofuran is added to a solution of 1 g of sodium borohydride in 20 ml of tetrahydrofuran at a temperature below 20°C. To this mixture was added a solution of 1.65 g (5.4 mM) of α-hydroxy-1,4,5,8-tetramethoxynaphthalene-2-acetonitrile obtained in Reference Example 2 in 10 ml of tetrahydrofuran at a temperature below 20°C, and then at room temperature. Continue stirring for 4 hours. The reaction mixture was transferred to water, extracted with methylene chloride, and the organic layer was dried, concentrated, and purified by silica gel column chromatography (methanol/chloroform) to obtain α-aminomethyl-1,4,5,8-tetra 500 mg of methoxynaphthalene-2-methanol are obtained as an oil. The structure and physical properties of the obtained compound are shown in Table 1. Example 2 α-aminomethyl-1,4,5,8-tetramethoxynaphthalene-2-methanol 310 mg
(1mM) and 300mg of acetone in 5ml of methanol, slowly add 65mg of NaBH 3 CN under ice cooling.
Thereafter, the temperature was gradually returned to room temperature and stirring was continued for 16 hours. The reaction solution was transferred to water, extracted with chloroform,
After drying and concentrating the organic layer, the resulting crude product was purified by silica gel chromatography (chloroform:methanol = 20:1 V/V) to obtain α-(1-methylethyl)aminomethyl-1,4,5 , 8-tetramethoxynaphthalene-2-methanol 272mg
(yield 78%). The structure and physical properties of the compound are shown in Table 1. Examples 3 to 9 Compounds of Examples 3 to 9 shown in Table 1 were obtained in the same manner as in Examples 1 and 2 above. Each of these compounds can also be produced according to the method described in Example 13 below. Example 10 750 mg of α-piperidinomethyl-1,4,5,8-tetramethoxynaphthalene-2-methanol was dissolved in 4 ml of pyridine, and 4 ml of acetic anhydride was added.
Stir at â for 3 hours. Transfer to water, extract with ethyl acetate, and wash the organic layer with water. After concentrating the organic layer, the resulting crude product was purified by silica gel chromatography (methanol/chloroform 1/30V/V).
740 mg (88%) of 2-(1-acetoxy-2-piperidinoethyl)-1,4,5,8-tetramethoxynaphthalene are obtained as an oil. Its structure and physical properties are shown in Table 1. Examples 11 and 12 Compounds of Examples 11 and 12 shown in Table 1 below were obtained in the same manner as in Example 10 above. [Table] [Table] [Table] Example 13 2-(1,2-epoxyethyl) obtained in Reference Example 1
-1,4,5,8-tetramethoxynaphthalene 1
g and 4 g of isopropylamine in methanol 60
ml and stirred at room temperature for 6 days. Thereafter, methanol was distilled off, and the obtained oily substance was purified by silica gel column chromatography (chloroform/methanol = 30/1 V/V) to 360 mg (yield: 3
%) of β-(1-methylethyl)amino-1,4,
5,8-tetramethoxynaphthalene-2-ethanol is obtained as an oil. This product could be obtained as a crystal by dissolving it in ethanol, drying it, acidifying it with hydrochloric acid, and adding ether, and its physical properties were consistent with those of the compound obtained in Example 2 above. In addition, in the above silica gel column chromatography, chloroform/methanol = 2
By continuing to develop at 0/1 (V/V ratio), 400
mg (yield 33%) of α-(1-methylethyl)aminomethyl-1,4,5,8-tetramethoxynaphthalene-2-methanol is obtained as an oil.
This oil is dissolved in ethanol, dried and
After making it acidic with hydrochloric acid, it can be collected as crystals by adding ether. The structure and physical properties of this compound are shown in Table 2 as Example No. 13. Examples 14 to 21 In the same manner as in Example 13, Examples 14 to 2 shown in Table 2 below were prepared along with each compound shown in Examples 3 to 9.
21 compounds were obtained. Examples 22-24 The same operations as in Example 10 were performed to obtain the compounds of Examples 22-24 shown in Table 2 below. [Table] [Table]
Claims (1)
R3ã¯äžæ¹ãæ°Žé žåºåã¯äœçŽã¢ã«ã«ãã€ã«ãªãã·
åºã瀺ãã仿¹ãåºãåŒãã瀺ãã該åºã«ã ããŠR4åã³R5ã¯åäžåã¯çžç°ãªã€ãŠæ°ŽçŽ ååã
äœçŽã¢ã«ãã«åºãã·ã¯ãã¢ã«ãã«åºãããšãã«ç°
äžã«çœ®æåºãšããŠäœçŽã¢ã«ã³ãã·åºãæããããš
ã®ããããšãã«åºåã¯ããšãã«ç°äžã«çœ®æåºãšã
ãŠäœçŽã¢ã«ã³ãã·åºãæããããšã®ããããšãã«
äœçŽã¢ã«ãã«åºã瀺ãããŸãR4åã³R5ã¯é žçŽ å
åãããã¯çªçŽ ååãä»ããããã¯ä»ããããšãª
ãäºã«çµåããŠã飿¥ããçªçŽ ååãšå ±ã«è€çŽ ç°
åºã圢æããŠãããã該è€çŽ ç°åºã¯æŽã«ããšãã«
äœçŽã¢ã«ãã«åºã眮æåºãšããŠæããŠããŠãã
ããã ã§è¡šããããïŒïŒïŒïŒïŒïŒïŒâããã©ã¢ã«ã³ãã·
ããã¿ã¬ã³èªå°äœåã³ãã®å¡©ã[Claims] 1. General formula [In the formula, R 1 represents a lower alkoxy group. R 2 and
One of R 3 represents a hydroxyl group or a lower alkanoyloxy group, and the other represents a group [Formula]. In this group, R 4 and R 5 are the same or different and are hydrogen atoms,
A lower alkyl group, a cycloalkyl group, a phenyl group that may have a lower alkoxy group as a substituent on the phenyl ring, or a phenyl lower alkyl group that may have a lower alkoxy group as a substituent on the phenyl ring. Furthermore, R 4 and R 5 may be bonded to each other with or without an oxygen atom or a nitrogen atom to form a heterocyclic group together with the adjacent nitrogen atom, and the heterocyclic group may further include a phenyl lower alkyl group. It may be included as a substituent. ] A 1,4,5,8-tetraalkoxynaphthalene derivative and a salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58209712A JPS60100542A (en) | 1983-11-07 | 1983-11-07 | 1,4,5,8-tetraalkoxynaphthalene derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58209712A JPS60100542A (en) | 1983-11-07 | 1983-11-07 | 1,4,5,8-tetraalkoxynaphthalene derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60100542A JPS60100542A (en) | 1985-06-04 |
| JPH0449536B2 true JPH0449536B2 (en) | 1992-08-11 |
Family
ID=16577393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58209712A Granted JPS60100542A (en) | 1983-11-07 | 1983-11-07 | 1,4,5,8-tetraalkoxynaphthalene derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60100542A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987002359A1 (en) * | 1985-10-14 | 1987-04-23 | Maggioni-Winthrop S.P.A. | Dihydrobenzothiophene and thiochromane aminoalcohols |
| WO1987002666A2 (en) * | 1985-10-31 | 1987-05-07 | Maggioni-Winthrop S.P.A. | Bicyclic alkoxy- and alkylthio-substituted aminoalcohols |
-
1983
- 1983-11-07 JP JP58209712A patent/JPS60100542A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60100542A (en) | 1985-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1005655A3 (en) | Process for producing 3-aryloxy-3-phenyl-propyl amines or their salts | |
| JPS6012350B2 (en) | Method for producing novel arylpiperidine derivatives | |
| LU86435A1 (en) | NOVEL MORPHINANE AND MORPHINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| JPS6330894B2 (en) | ||
| JPH0449536B2 (en) | ||
| US4705807A (en) | Amine derivatives | |
| AU609067B2 (en) | Compounds useful as intermediates for the production of substituted 1-pyridyloxy-3-indolyalkylamino-2- propanols | |
| US4927968A (en) | Chemical intermediates and process | |
| EP2730562A1 (en) | Novel method for synthesising (2E)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid | |
| JPS6236518B2 (en) | ||
| JP3492433B2 (en) | 3- (Phenylalkylaminoalkyloxy) -5-phenylpyrazole compounds, methods and intermediates for their preparation and cardiovascular agents containing them | |
| US6781003B1 (en) | Preparation of pure citalopram | |
| US4020071A (en) | Derivatives of 1-phenoxy-3-amino-propan-2-ol | |
| EP1661894A1 (en) | Process for production of 4-aminotetrahydropyrans and salts thereof with acids, intermediates for the process, and process for production thereof | |
| EP2719689B1 (en) | Novel method for synthesising 3-(2-bromo-4,5-dimethoxyphenyl) propanenitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid | |
| JPH0314296B2 (en) | ||
| KR100353661B1 (en) | Method for preparing β-nitroenamine and its intermediates | |
| EP0306411A2 (en) | Ethanone oximes | |
| JP2801647B2 (en) | Method for producing 6-fluorochromone-2-carboxylic acid derivative | |
| KR840001077B1 (en) | Process for n4-carbamoylpiperazino propanal derivatives | |
| US6812355B2 (en) | Process for the manufacture of citalopram hydrobromide from 5-bromophthalide | |
| US20060293530A1 (en) | Process for the manufacture of citalopram hydrobromide | |
| JP2539261B2 (en) | Imidazole derivative | |
| JP4973210B2 (en) | New synthesis method | |
| JPH0827109A (en) | Method for producing β- (benzyl) indole-3-ethanol |